Unity Biotechnology, Inc.

Biotechnology • Healthcare • South San Francisco, CA, United States • UNBX (PNK)

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, an a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Wikipedia

Stock Performance (90 Days)

Data through Oct 14, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Unity Biotechnology stockholders approve company liquidation and dissolution plan - Investing.com

Investing.com • Sep 19

Unity Stock Crashes Nearly 50% After Nasdaq Delisting Notice - Yahoo Finance

Yahoo Finance • Jun 30

UNITY Biotechnology Announces Complete 36-Week Results from - GlobeNewswire

GlobeNewswire • May 5

Unity's eye treatment fails to match Eylea, though analysts still see a path forward - Fierce Biotech

Fierce Biotech • Mar 24

Profit Review: How rising interest rates impact Unity Biotechnology Inc stock - July 2025 Trade Ideas & AI Forecasted Entry/Exit Points - moha.gov.vn

moha.gov.vn • Dec 27

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Unity Biotechnology, Inc. had layoffs?

No layoff events have been recorded for Unity Biotechnology, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Unity Biotechnology, Inc. have?

Unity Biotechnology, Inc. has approximately 16 employees.

What industry is Unity Biotechnology, Inc. in?

Unity Biotechnology, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Unity Biotechnology, Inc. a publicly traded company?

Yes, Unity Biotechnology, Inc. is publicly traded under the ticker symbol UNBX on the PNK. The company has a market capitalization of approximately $0.00 billion.

Where is Unity Biotechnology, Inc. headquartered?

Unity Biotechnology, Inc. is headquartered in South San Francisco, CA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.